MARKET

TBIO

TBIO

TRANSLATE BIO, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.56
+0.33
+1.48%
Opening 11:06 03/08 EST
OPEN
22.18
PREV CLOSE
22.23
HIGH
22.67
LOW
21.64
VOLUME
145.87K
TURNOVER
--
52 WEEK HIGH
34.64
52 WEEK LOW
6.80
MARKET CAP
1.70B
P/E (TTM)
-20.3152
1D
5D
1M
3M
1Y
5Y
Billionaire Seth Klarman’s Top 10 Stock Picks for 2021
In this article, we discussed billionaire Seth Klarman’s top 10 stock picks for 2021. You can skip our detailed analysis of Klarman’s latest moves and go to Billionaire Seth Klarman’s Top 5 Stock Picks for 2021. Value investing legend billionaire Seth Klar...
Insider Monkey · 3d ago
Translate Bio, Inc. (TBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 3d ago
Analysts Just Made A Huge Upgrade To Their Translate Bio, Inc. (NASDAQ:TBIO) Forecasts
Celebrations may be in order for Translate Bio, Inc. ( NASDAQ:TBIO ) shareholders, with the analysts delivering a...
Simply Wall St. · 4d ago
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today reported that on March 1, 2021, the...
GlobeNewswire · 4d ago
10-K: TRANSLATE BIO, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/01 13:50
DJ Translate Bio Price Target Cut to $33.00/Share From $34.00 by SVB Leerink
Dow Jones · 03/01 12:11
DJ Translate Bio Is Maintained at Outperform by SVB Leerink
Dow Jones · 03/01 12:11
Translate Bio Reports Narrower Q4 Loss, Higher Collaboration Revenue
MT Newswires · 02/26 06:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TBIO. Analyze the recent business situations of TRANSLATE BIO, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TBIO stock price target is 32.50 with a high estimate of 40.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 222
Institutional Holdings: 67.35M
% Owned: 89.54%
Shares Outstanding: 75.21M
TypeInstitutionsShares
Increased
52
2.28M
New
57
609.96K
Decreased
43
7.39M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.20%
Pharmaceuticals & Medical Research
+1.09%
Key Executives
Chairman/Independent Director
Daniel Lynch
President/Chief Executive Officer/Chief Financial Officer/Director
Ronald Renaud
Founder/Executive Vice President
Michael Heartlein
Chief Operating Officer
Paul Burgess
Chief Human Resource Officer
Paula Cloghessy
Chief Technology Officer
Frank DeRosa
Chief Accounting Officer
Robert Prentiss
Chief Scientific Officer
Richard Wooster
Other
Ann Barbier
Other
Brian Fenton
Independent Director
Daniella Beckman
Independent Director
George Demetri
Independent Director
Jean-Francois Formela
Independent Director
Owen Hughes
Independent Director
Robert Meyer
Independent Director
Robert Plenge
No Data
  • All
  • Financials
  • Insiders
More
About TBIO
Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT product candidate for the lung, MRT5005, is designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization.

Webull offers kinds of Translate Bio Inc stock information, including NASDAQ:TBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBIO stock methods without spending real money on the virtual paper trading platform.